{
  "id": 7908130,
  "title": "BillionToOne CEO Oguzhan Atay sells $2.5m in company stock",
  "url": "https://urgent.news/2026/09/17/billiontoone-ceo-oguzhan-atay-sells-2-5m-in-company-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-17T00:01:07.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/billiontoone-ceo-oguzhan-atay-sells-25m-in-company-stock-93CH-4904708"
  },
  "original_language": "en",
  "account": "Oguzhan Atay, Chairman and CEO of BillionToOne, Inc., sold 24,059 shares of Class A Common Stock on September 14, 2026, for $2.5 million. The sales occurred under a pre-approved Rule 10b5-1 trading plan. Each share was sold between $98.6314 and $101.4919, generating a total of $2,507,908. Following these transactions, Atay no longer owned any Class A Common Stock directly. Meanwhile, his spouse also sold 5,332 shares on the same date, earning $522,536 through a separate Rule 10b5-1 plan. After these sales, Atay indirectly owned 157,168 shares through his spouse. Earlier, Atay exercised options to buy 24,999 shares at $2.8 per share, totaling $69,997. BillionToOne shares have surged 48.5% over the past six months, reaching $103.61. Analysts consider the stock overvalued, placing it among highly valued stocks. BillionToOne reported second-quarter earnings that surpassed expectations, with a per-share profit of $0.15, up from the forecasted $0.03. Revenue increased 64% to $109.4 million. Despite this growth, the stock saw a sharp decline in after-hours trading, possibly due to investor concerns about the company's future outlook and growth sustainability. Canaccord Genuity initiated coverage on BillionToOne with a buy rating and a price target of $120.00, citing the company's proprietary technologies in prenatal and oncology diagnostics.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Alignment healthcare CEO John Kao sells $356,200 in ALHC stock",
        "url": "https://urgent.news/2026/09/16/alignment-healthcare-ceo-john-kao-sells-356-200-in-alhc-stock",
        "published": "2026-09-16T23:15:51.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}